Diferencia entre revisiones de «Protamine sulfate»
Sin resumen de edición |
(Switch SMW query from broadtable to table format for better layout with TOC) |
||
| (No se muestran 6 ediciones intermedias de 3 usuarios) | |||
| Línea 6: | Línea 6: | ||
==Adult Dosing== | ==Adult Dosing== | ||
{{Heparin reversal}} | |||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
| Línea 40: | Línea 33: | ||
==Pharmacology== | ==Pharmacology== | ||
*Half-life: | *Half-life: | ||
** ~7 minutes | |||
*Metabolism: | *Metabolism: | ||
*Excretion: | *Excretion: | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
*Weak anticoagulant, heparin antagonist | *Weak anticoagulant, heparin antagonist | ||
==Comments== | ==Comments== | ||
==Indications by Condition== | |||
''The following table is automatically generated from disease/condition pages across WikEM.'' | |||
{{#ask:[[Has DrugName::Protamine]] | |||
|?Has Indication=Indication | |||
|?Has Dose=Dose | |||
|?Has Context=Context | |||
|?Has Route=Route | |||
|?Has Population=Population | |||
|format=table | |||
|headers=plain | |||
|mainlabel=- | |||
|sort=Has Indication | |||
|limit=50 | |||
}} | |||
==See Also== | ==See Also== | ||
| Línea 52: | Línea 63: | ||
==References== | ==References== | ||
<references/> | <references/> | ||
* Protamine sulfate: Drug information. UpToDate. www.uptodate.com. Accessed April 2, 2019. | |||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
Revisión actual - 21:56 20 mar 2026
Administration
- Type: Antidote
- Dosage Forms:
- Routes of Administration: IV
- Common Trade Names:
Adult Dosing
- Major bleeding due to unfractionated heparin:
- 1 mg IV for every 100 units of heparin infused in past 3h
- Do not infuse faster than 50mg/10min
- If it has been >30min since last heparin injection, 0.5mg may be sufficient
- Give slowly over 1-3min; do not exceed 50mg in any 10 minute period (anaphylaxis risk)
- Because half-life is short (7 min) may require second treatment
- Major bleeding due to low-molecular-weight heparin:
- Protamine is less effective for bleeding from LMWH than it is with heparin-induced bleeds
- Enoxaparin: 1 mg IV for every 1 mg enoxaparin administered in past 8h
- Dalteparin: 1 mg IV for every 100 anti-Xa international units of dalteparin
Pediatric Dosing
Safety/Efficacy not well established in pediatrics, but unofficial suggested dosing similar to adult dosing
Special Populations
- Pregnancy Rating: C
- Lactation risk: Infant risk cannot be ruled out
- Renal dosing: no adjustment
- Hepatic dosing: no adjustment
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- Anaphylaxis(0.2% of patients), anaphylactoid reaction
- Circulatory collapse, capillary leak, bradyarrhythmia, hypotension
- Pulmonary edema
Common
- Flushing
- Dyspnea
- Nausea/vomiting
Pharmacology
- Half-life:
- ~7 minutes
- Metabolism:
- Excretion:
Mechanism of Action
- Weak anticoagulant, heparin antagonist
Comments
Indications by Condition
The following table is automatically generated from disease/condition pages across WikEM.
| Indication | Dose | Context | Route | Population |
|---|---|---|---|---|
| Anticoagulant reversal for life-threatening bleeds | 50mg IV (<8hr since last dose), 25mg (8-12hr) | Heparin/LMWH reversal | IV | Adult |
See Also
- Anticoagulant reversal, Unfractionated heparin reversal
- Unfractionated heparin, Low molecular weight heparin
References
- Protamine sulfate: Drug information. UpToDate. www.uptodate.com. Accessed April 2, 2019.